rethinkPeptides Search
Menu
Study breakdown

How Antimicrobial Peptides Select Their Targets: Insights from Lipid Monolayer Studies

evidence
The takeaway

A critical review of lipid monolayer studies reveals how antimicrobial peptides achieve selective membrane disruption based on specific lipid signatures of bacteria, cancer, and senescent cells.

Lipid-driven selectivity

AMPs distinguish target cells through specific membrane lipid signatures

What the researchers found

Lipid monolayer models reveal that AMP selectivity is driven by specific lipid signatures that differentiate bacterial, cancerous, and senescent cell membranes from healthy cells.

Why it matters

Understanding how AMPs distinguish between harmful and healthy cells is essential for designing peptide therapies that kill pathogens or cancer cells without damaging normal tissue.

How the study worked

Critical review of lipid monolayer biophysical studies examining antimicrobial peptide-membrane interactions and selectivity mechanisms.

What this study cannot tell us

Monolayer models are reductionist — they mimic only the outer leaflet and lack the complexity of real bilayer membranes with proteins and carbohydrates.

How to read the evidence

Critical review of biophysical studies — provides mechanistic understanding but monolayer models have inherent limitations.

When this study was published

Published 2026 in Advances in Colloid and Interface Science.

The bigger picture

AMPs represent a potential alternative to antibiotics for infections and a novel approach for cancer and anti-aging therapies, but selectivity must be precisely understood and controlled.

Questions still open

  • Can monolayer-derived selectivity predictions be validated in whole-cell assays?
  • Do AMPs maintain selectivity in complex in vivo environments?

Common questions

How do antimicrobial peptides know which cells to attack?
AMPs recognize differences in cell membrane lipid composition. Bacterial membranes have distinct lipids that attract AMPs, while healthy human cells have a different lipid profile that AMPs tend to avoid.
Can antimicrobial peptides fight cancer?
Some AMPs show activity against cancer cells, which have altered membrane compositions. Research is ongoing to develop peptides that selectively target cancer while sparing healthy tissue.

Read the original research

Antimicrobial peptides at (lipid) interfaces: Insights from monolayer models.

Advances in colloid and interface science, 350, 103775

Citation

Antelo-Riveiro, Paula; Garcia-Fandino, Rebeca; Piñeiro, Ángel. (2026). Antimicrobial peptides at (lipid) interfaces: Insights from monolayer models.. Advances in colloid and interface science, 350, 103775. https://doi.org/10.1016/j.cis.2025.103775